Sandoz TV Episode 18: Trailer
Find out what to expect from the newest episode of Sandoz TV.
|Global News||Sandoz Around the World||Sandoz in the Media|
Sandoz' Mark McCamish discusses US Biosimilars landscape on Biocentury TV
October 14, 2014
Yesterday, Dr. Mark McCamish, Head Global Biopharmaceutical Development at Sandoz discussed the key issues around biosimilars in the US on "BioCentury This Week".
Sandoz wins Generics Bulletin 'Biosimilars Initiative of the Year' award
Holzkirchen, October 13, 2014
Sandoz is pleased to announce that Generics Bulletin, a newsletter covering commercial and regulatory information for the global generics industry, has awarded the company with “Biosimilars Initiative of the Year”, for its file acceptance of G-CSF (filgrastim) in the US. Sandoz also achieved top-three podium positions in the Company of the Year; Company of the Year – Americas; and Innovation of the Year Awards categories.
Sandoz receives approval in Portugal for innovative respiratory inhaler AirFluSal® Forspiro®
Holzkirchen, October 09, 2014
Sandoz announces today that the Portuguese Health Authority (Infarmed) has granted marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).
US celebrates 30 years of rapid generics growth
October 01, 2014
30 years ago, when President Ronald Reagan signed the legislation that would lay the basis for today’s US generics industry, even the law’s biggest fans never guessed quite how successful it would be.
Sandoz contributes to fighting the number one cause of death globally
September 29, 2014
Cardiovascular disease (CVD) is a global burden accounting for 17.3 million deaths a year